Barclays analyst Eliana Merle notes that an item posted in the Vynamax/tafamidis intellectual property case docket states Pfizer (PFE) and Hikma stipulate and agree to dismissal, which from the firm’s understanding means all defendants have settled. The firm, which thinks this is “a key positive” for BridgeBio (BBIO) removing an overhang on the stock, has an Overweight rating on BridgeBio shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- 3 Best Stocks to Buy This Week, According to Analysts – April 26-May 1
- BridgeBio Buy Rating Reiterated as Analyst Sees Extended Patent Runway, Delayed Tafamidis Competition and Maintains $100 Price Target
- Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
- BridgeBio initiated with an Outperform at RBC Capital
- BridgeBio: Advancing First-in-Class LGMD Therapy and Blockbuster ATTR Franchise Underpin Reiterated Buy and $100 Target